Metabolic Acidosis (MA) Drugs Market Share | Metabolic Acidosis (MA) Epidemiology


Metabolic Acidosis (MA)
Metabolic Acidosis (MA) is a serious electrolyte disorder characterized by an imbalance in the body’s acid-base balance. Metabolic acidosis can lead to acidemia, which is defined as an arterial blood pH lower than 7.37, which itself is a result of acidosis - the process in the body that causes a low pH in blood and tissues.



Metabolic Acidosis Epidemiology  
In the United States, approximately one in seven adults has Chronic Kidney Disease (CKD). Patients with CKD may have a reduced ability to excrete acid generated by the metabolism of food, especially protein, resulting in metabolic acidosis. Metabolic acidosis results in lower blood pH and decreased blood bicarbonate levels. Chronic metabolic acidosis can lead to accelerated progression of kidney disease, an increased rate of mortality, progressive muscle breakdown and exacerbation of the bone disease. In the United States, chronic metabolic acidosis affects a significant percentage of CKD patients resulting in approximately 3 million to 4 million adults with chronic metabolic acidosis.[Nimrit Goraya et al., 2019]


Metabolic Acidosis Drug Chapters
Tricida is developing veverimer (TRC101) as a potential novel treatment
for metabolic acidosis. A New Drug Application was filed in September
2019 and expects to launch the drug in 2020 assuming FDA approval.


Metabolic Acidosis Market Outlook
The dynamics of Metabolic Acidosis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, expansion beyond nephrologists, urgent need of treatment and incremental healthcare spending across the world.

According to DelveInsight, Metabolic Acidosis market in 7MM is expected to change in the study period 2017-2030.

Report Highlights
  1. In the coming years, Metabolic Acidosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world.
  2. The companies and academics are working to assess challenges and seek opportunities that could influence Metabolic Acidosis R&D.       
  3. Major players are involved in developing therapies for Metabolic Acidosis.
  4. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Metabolic Acidosis
View a detailed report on Metabolic Acidosis: https://www.delveinsight.com/report-store/metabolic-acidosis-market
Related reports: Metabolic Acidosis Epidemiology Forecast to 2030
                                 Metabolic Acidosis Pipeline Insights, 2020




Comments

  1. UnknownMarch 7, 2020 at 8:35 PM

    Strange "water hack" burns 2 lbs in your sleep

    Well over 160k women and men are using a simple and secret "water hack" to burn 2 lbs each night while they sleep.

    It is very simple and works on everybody.

    Here are the easy steps for this hack:

    1) Take a drinking glass and fill it half full

    2) And now use this weight loss HACK

    so you'll become 2 lbs thinner the very next day!

    ReplyDelete

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more